From laboratory to clinic: Bridging regulatory and manufacturing gaps in stem cell-based therapies

Figure 2 Diagrammatic representation of cell sourcing approaches for advanced therapy medicinal products. The schematic contrasts autologous, allogeneic, and induced pluripotent stem cell methodologies, emphasizing distinctions in donor heterogeneity, immune compatibility, scalability, and reproducibility of production. Key elements, including sterile cell banking and the application of good manufacturing practice-compliant culture media, are illustrated as critical measures for maintaining cell quality and safety. GMP: Good manufacturing practice.